Design considerations for nanotherapeutics in oncology

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 8, 2015, Pages 1893-1907

  Stylianopoulos, Triantafyllos ^a   Jain, Rakesh K ^b  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer therapy; Controlled drug release; EPR effect; Nanomedicine; Nanoparticle targeting

Indexed keywords

DISEASES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; ONCOLOGY; TUMORS;

CANCER THERAPY; CHEMOTHERAPEUTIC AGENTS; CONTROLLED DRUG RELEASE; ENHANCED PERMEABILITY AND RETENTION EFFECT; EPR EFFECT; NANOPARTICLE FORMULATION; NANOPARTICLE TARGETING; TUMOR MICROENVIRONMENT;

DESIGN;

NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION;

BINDING AFFINITY; CANCER PATIENT; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INTRACELLULAR TRANSPORT; NANOMEDICINE; NANOTECHNOLOGY; ONCOLOGY; OVERALL SURVIVAL; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; QUALITY OF LIFE;

EID: 84951143213     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.07.015     Document Type: Review

References (149)

1. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
2. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412-2417.
3. Chauhan V.P., Jain R.K. Strategies for advancing cancer nanomedicine. Nat Mater 2013, 12:958-962.
4. Gerlowski L.E., Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986, 31:288-305.
5. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 1986, 46:6387-6392.
6. Jain R.K. Barriers to drug delivery in solid tumors. Sci Am 1994, 271:58-65.
7. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001, 46:149-168.
8. Chauhan V.P., Stylianopoulos T., Boucher Y., Jain R.K. Delivery of molecular and nanomedicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011, 2:281-298.
9. Netti P.A., Roberge S., Boucher Y., Baxter L.T., Jain R.K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996, 52:27-46.
10. Stylianopoulos T., Jain R.K. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 2013, 110:18632-18637.
11. Jain R.K., Martin J.D., Stylianopoulos T. The role of mechanical forces in tumor progression and therapy. Annu Rev Biomed Eng 2014, 16:321-346.
12. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988, 48:7022-7032.
13. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990, 50:4478-4484.
14. Boucher Y., Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992, 52:5110-5114.
15. Nugent L.J., Jain R.K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res 1984, 44:238-244.
16. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6:815-823.
17. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7:383-388.
18. Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv 2013, 4:421-423.
19. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
20. Bourzac K. Nanotechnology: carrying drugs. Nature 2012, 491:S58-S60.
21. Sheridan C. Proof of concept for next-generation nanoparticle drugs in humans. Nat Biotechnol 2012, 30:471-473.
22. Venditto V.J., Szoka F.C. Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 2013, 65:80-88.
23. Dawidczyk C.M., Russell L.M., Searson P.C. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem 2014, 2:69.
24. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66:2-25.
25. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445-2451.
26. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312-3322.
27. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
28. Gill P.S., Wernz J., Scadden D.T., Cohen P., Mukwaya G.M., von Roenn J.H., et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14:2353-2364.
29. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:1444-1454.
30. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
31. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.
32. Qiang C., Qizhong Z., Jian L., Liqing L., Wenhua Z., Yajie W. Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-smal-cell lung cancer. Chin J Oncol 2003, 25:190-192.
33. Koudelka S., Turanek J. Liposomal paclitaxel formulations. J Control Release 2012, 163:322-334.
34. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
35. Chen L.T., Von Hoff D.D., Li C.P., Wang-Gillam A., Bodoky G., Dean A., et al. Expanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol 2015, 33(Suppl. 3). [abstr 234].
36. Jain M.M., Patil S., Pathak A.B., Deshmukh C.D., Bhatt N., Babu K.G., et al. The efficacy and safety of paclitaxel injection concentrate for nano-dispersion (PICN) at two different doses versus paclitaxel albumin-stabilized nanoparticle formulation in subjects with metastatic breast cancer (MBC). J Clin Oncol 2014, 32. [Suppl.; abstr 1069].
37. Akhter S., Ahmad I., Ahmad M.Z., Ramazani F., Singh A., Rahman Z., et al. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets 2013, 13:362-378.
38. Svenson S. What nanomedicine in the clinic right now really forms nanoparticles?. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014, 6:125-135.
39. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004, 15:517-525.
40. Senzer N., Nemunaitis J., Nemunaitis D., Bedell C., Edelman G., Barve M., et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 2013, 21:1096-1103.
41. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39. 10.1126/scitranslmed.3003651.
42. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
43. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
44. Roy A.C., Park S.R., Cunningham D., Kang Y.K., Chao Y., Chen L.T., et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013, 24:1567-1573.
45. Zuckerman J.E., Gritli I., Tolcher A., Heidel J.D., Lim D., Morgan R., et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A 2014, 111:11449-11454.
46. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010, 2:14.
47. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) 2008, 3:703-717.
48. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
49. Choi H.S., Liu W., Liu F., Nasr K., Misra P., Bawendi M.G., et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010, 5:42-47.
50. Zamboni W.C., Torchilin V., Patri A.K., Hrkach J., Stern S., Lee R., et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012, 18:3229-3241.
51. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009, 9:1909-1915.
52. Popovic Z., Liu W., Chauhan V.P., Lee J., Wong C., Greytak A.B., et al. A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl 2010, 49:8649-8652.
53. Singh R., Pantarotto D., Lacerda L., Pastorin G., Klumpp C., Prato M., et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A 2006, 103:3357-3362.
54. Geng Y., Dalhaimer P., Cai S., Tsai R., Tewari M., Minko T., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2:249-255.
55. Chauhan V.P., Popovic Z., Chen O., Cui J., Fukumura D., Bawendi M.G., et al. Fluorescent nanorods and nanospheresfor real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011, 50:11417-11420.
56. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
57. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990, 268:235-237.
58. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991, 88:11460-11464.
59. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B: Biointerfaces 2000, 18:301-313.
60. Perry J.L., Reuter K.G., Kai M.P., Herlihy K.P., Jones S.W., Luft J.C., et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 2012, 12:5304-5310.
61. Perry J.L., Kai M.P., Reuter K.G., Bowerman C., Christopher Luft J., DeSimone J.M. Calibration-quality cancer nanotherapeutics. Cancer Treat Res 2015, 166:275-291.
62. Garcia I., Marradi M., Penades S. Glyconanoparticles: multifunctional nanomaterials for biomedical applications. Nanomedicine (Lond) 2010, 5:777-792.
63. Pombo Garcia K., Zarschler K., Barbaro L., Barreto J.A., O'Malley W., Spiccia L., et al. Zwitterionic-coated "stealth" nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small 2014, 10:2516-2529.
64. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607-4612.
65. Boucher Y., Kirkwood J.M., Opacic D., Desantis M., Jain R.K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991, 51:6691-6694.
66. Less J.R., Posner M.C., Boucher Y., Borochovitz D., Wolmark N., Jain R.K. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992, 52:6371-6374.
67. Yuan F., Salehi H.A., Boucher Y., Vasthare U.S., Tuma R.F., Jain R.K. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994, 54:4564-4568.
68. Wiig H., Swartz M.A. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 2012, 92:1005-1060.
69. Stylianopoulos T., Soteriou K., Fukumura D., Jain R.K. Cationic nanoparticles have superior transvascular flux into solid tumors: Insights from a mathematical model. Ann Biomed Eng 2013, 41(1):68-77.
70. Yue J., Liu S., Xie Z., Xing Y., Jing X. Size-dependent biodistribution and antitumor efficacy of polymer micelle drug delivery systems. J Mater Chem B 2013, 1:4273-4280.
71. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012, 62:112-120.
72. Dotan E., Starodub A., Berlin J., Lieu C.H., Guarino M.J., Marshall J., et al. A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: initial results of a phase I/II study. ASCO Annual Meeting 2015 2015, [Abstr 2505].
73. Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev 2012, 64:710-719.
74. Dellian M., Yuan F., Trubetskoy V.S., Torchilin V.P., Jain R.K. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000, 82:1513-1518.
75. Schmitt-Sody M., Strieth S., Krasnici S., Sauer B., Schulze B., Teifel M., et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003, 9:2335-2341.
76. Krasnici S., Werner A., Eichhorn M.E., Schmitt-Sody M., Pahernik S.A., Sauer B., et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003, 105:561-567.
77. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002, 62:6831-6836.
78. Yim H., Park S.J., Bae Y.H., Na K. Biodegradable cationic nanoparticles loaded with an anticancer drug for deep penetration of heterogeneous tumours. Biomaterials 2013, 34:7674-7682.
79. Han H.S., Martin J.D., Lee J., Harris D.K., Fukumura D., Jain R.K., et al. Spatial charge configuration regulates nanoparticle transport and binding behavior in vivo. Angew Chem Int Ed Engl 2013, 52:1414-1419.
80. Zhou Z., Ma X., Jin E., Tang J., Sui M., Shen Y., et al. Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery. Biomaterials 2013, 34:5722-5735.
81. Gentile F., Chiappini C., Fine D., Bhavane R.C., Peluccio M.S., Cheng M.M., et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech 2008, 41:2312-2318.
82. Smith B.R., Kempen P., Bouley D., Xu A., Liu Z., Melosh N., et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett 2012, 12:3369-3377.
83. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001, 98:4628-4633.
84. Stylianopoulos T., Poh M.Z., Insin N., Bawendi M.G., Fukumura D., Munn L.L., et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J 2010, 99:1342-1349.
85. Stylianopoulos T., Diop-Frimpong B., Munn L.L., Jain R.K. Diffusion anisotropy in collagen gels and tumors: the effect of fiber network orientation. Biophys J 2010, 99:3119-3128.
86. Baxter L.T., Jain R.K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989, 37:77-104.
87. Jain R.K., Tong R.T., Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007, 67:2729-2735.
88. Ramanujan S., Pluen A., McKee T.D., Brown E.B., Boucher Y., Jain R.K. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J 2002, 83:1650-1660.
89. McKee T.D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J.P., et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006, 66:2509-2513.
90. Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 2011, 108:2909-2914.
91. Huo S., Ma H., Huang K., Liu J., Wei T., Jin S., et al. Superior penetration and retention behavior of 50nm gold nanoparticles in tumors. Cancer Res 2013, 73:319-330.
92. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54:3352-3356.
93. Lieleg O., Baumgartel R.M., Bausch A.R. Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J 2009, 97:1569-1577.
94. Pluen A., Netti P.A., Jain R.K., Berk D.A. Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations. Biophys J 1999, 77:542-552.
95. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
96. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A 2005, 102:9469-9474.
97. Foged C., Brodin B., Frokjaer S., Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005, 298:315-322.
98. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
99. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3:145-150.
100. Rudolph C., Plank C., Lausier J., Schillinger U., Muller R.H., Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 2003, 278:11411-11418.
101. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
102. Thorek D.L., Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 2008, 29:3583-3590.
103. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 2003, 28:145-151.
104. Harush-Frenkel O., Rozentur E., Benita S., Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 2008, 9:435-443.
105. Huang X., Teng X., Chen D., Tang F., He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010, 31:438-448.
106. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A 2006, 103:4930-4934.
107. Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 2014, 13:813-827.
108. Gianella A., Mieszawska A.J., Hoeben F.J., Janssen H.M., Jarzyna P.A., Cormode D.P., et al. Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem Commun (Camb) 2013, 49:9392-9394.
109. McQuade C., Al Zaki A., Desai Y., Vido M., Sakhuja T., Cheng Z., et al. A multifunctional nanoplatform for imaging, radiotherapy, and the prediction of therapeutic response. Small 2015, 11:834-843.
110. Das M., Duan W., Sahoo S.K. Multifunctional nanoparticle-EpCAM aptamer bioconjugates: a paradigm for targeted drug delivery and imaging in cancer therapy. Nanomedicine 2015, 11:379-389.
111. Li J., Cai P., Shalviri A., Henderson J.T., He C., Foltz W.D., et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano 2014, 8:9925-9940.
112. Zhu L., Kate P., Torchilin V.P. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6:3491-3498.
113. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012, 33:583-591.
114. Park J.H., von Maltzahn G., Zhang L., Derfus A.M., Simberg D., Harris T.J., et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 2009, 5:694-700.
115. Zhu L., Torchilin V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb) 2013, 5:96-107.
116. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013, 12:991-1003.
117. Blum A.P., Kammeyer J.K., Rush A.M., Callmann C.E., Hahn M.E., Gianneschi N.C. Stimuli-responsive nanomaterials for biomedical applications. J Am Chem Soc 2015, 137:2140-2154.
118. von Maltzahn G., Park J.H., Agrawal A., Bandaru N.K., Das S.K., Sailor M.J., et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res 2009, 69:3892-3900.
119. Fomina N., Sankaranarayanan J., Almutairi A. Photochemical mechanisms of light-triggered release from nanocarriers. Adv Drug Deliv Rev 2012, 64:1005-1020.
120. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 2012, 24:3747-3756.
121. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002, 99:12617-12621.
122. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
123. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5:73-82.
124. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
125. Kinsella J.M., Jimenez R.E., Karmali P.P., Rush A.M., Kotamraju V.R., Gianneschi N.C., et al. X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Ed Engl 2011, 50:12308-12311.
126. Winer I., Wang S., Lee Y.E., Fan W., Gong Y., Burgos-Ojeda D., et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 2010, 70:8674-8683.
127. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
128. Fujimori K., Covell D.G., Fletcher J.E., Weinstein J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990, 31:1191-1198.
129. Baxter L.T., Jain R.K. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc Res 1991, 41:252-272.
130. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
131. Stylianopoulos T., Economides E.A., Baish J., Fukumura D., Jain R.K. Optimal design of cancer nanomedicines: multi-stage nanoparticle delivery systems for the treatment of solid tumors. Ann Biomed Eng 2015, 43:2291-2300. 10.1007/s10439-015-1276-9.
132. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161:175-187.
133. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
134. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
135. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol 2008, 26:552-558.
136. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010, 7:1195-1208.
137. Sanson C., Schatz C., Le Meins J.F., Soum A., Thevenot J., Garanger E., et al. A simple method to achieve high doxorubicin loading in biodegradable polymersomes. J Control Release 2010, 147:428-435.
138. Gong J., Huo M., Zhou J., Zhang Y., Peng X., Yu D., et al. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm 2009, 376:161-168.
139. Gong J., Chen M., Zheng Y., Wang S., Wang Y. Polymeric micelles drug delivery system in oncology. J Control Release 2012, 159:312-323.
140. Merkel T.J., Jones S.W., Herlihy K.P., Kersey F.R., Shields A.R., Napier M., et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A 2011, 108:586-591.
141. Agarwal R., Roy K. Intracellular delivery of polymeric nanocarriers: a matter of size, shape, charge, elasticity and surface composition. Ther Deliv 2013, 4:705-723.
142. Wong C., Stylianopoulos T., Cui J., Martin J., Chauhan V.P., Jiang W., et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 2011, 108:2426-2431.
143. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
144. Stylianopoulos T., Wong C., Bawendi M.G., Jain R.K., Fukumura D. Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol 2012, 508:109-130.
145. Stylianopoulos T., Martin J.D., Chauhan V.P., Jain S.R., Diop-Frimpong B., Bardeesy N., et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 2012, 109:15101-15108.
146. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
147. Liu J., Liao S., Diop-Frimpong B., Chen W., Goel S., Naxerova K., et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A 2012, 109:16618-16623.
148. Chauhan V.P., Martin J.D., Liu H., Lacorre D.A., Jain S.R., Kozin S.V., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. Nat Commun 2013, 4. 10.1038/ncomms.3516.
149. Chauhan V.P., Boucher Y., Ferrone C.R., Roberge S., Martin J.D., Stylianopoulos T., et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 2014, 26:14-15.